CD276 and osteosarcoma: Given these findings, we explored a novel, proof-of-principle, high-throughput, high-content screen to identify drugs with the ability to increase B7-H3 expression in osteosarcoma cells, which could potentiate B7-H3-CAR T cell effector function.